Asthma

ClinicalAugust 4, 2026

Study on Fluticasone Propionate/Albuterol Combination for Asthma Exacerbation Prevention

The study aims to evaluate the efficacy of a fixed-dose combination of fluticasone propionate and albuterol sulfate in preventing severe asthma exacerbations over a treatment period of up to 42 months.

CompetitiveAugust 1, 2026

Cipla's ANDA213087 for Fluticasone Propionate and Salmeterol Xinafoate Receives AP Status

Cipla's application ANDA213087 for Fluticasone Propionate and Salmeterol Xinafoate has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 31, 2026

FDA Acceptance of SYMBICORT AEROSPHERE Supplement by AstraZeneca

The FDA has accepted the supplemental NDA for SYMBICORT AEROSPHERE, indicating a step forward in its regulatory process.

CompetitiveJuly 31, 2026

GRANITE Study Evaluates Airsupra vs Albuterol for Asthma Exacerbation Risk

The GRANITE study is assessing the real-world effectiveness of Airsupra compared to albuterol in reducing asthma exacerbations.

RegulatoryJuly 29, 2026

FDA Accepts Application for Budesonide and Formoterol Fumarate Dihydrate

The FDA has accepted the application ANDA212212 for Budesonide and Formoterol Fumarate Dihydrate submitted by Teva Pharmaceuticals.

ClinicalJuly 24, 2026

Qufeng Xuanbi Formula shows potential in treating allergic asthma via immune-metabolic regulation

Qufeng Xuanbi Formula has demonstrated anti-asthmatic activity and may influence airway remodeling through metabolic pathways.

ClinicalJuly 23, 2026

Study on Buteyko Breathing Technique's Impact on Childhood Asthma Control

A study is examining the effect of the Buteyko breathing technique on asthma control and quality of life in children aged 7-12.

RegulatoryJuly 22, 2026

MHRA Approves First Lower-Carbon Beclometasone Inhalers for Asthma

The MHRA has approved the world's first lower-carbon beclometasone inhalers, utilizing a next-generation propellant.

RegulatoryJuly 17, 2026

FDA Approves TRIMBOW (NDA219622) by Chiesi

The FDA has approved TRIMBOW, a combination inhaler containing beclomethasone dipropionate, formoterol fumarate, and glycopyrrolate.

RegulatoryJuly 16, 2026

FDA Accepts Supplemental Application for Fasenra (Benralizumab) by AstraZeneca

The FDA has accepted a supplemental application for Fasenra (benralizumab) from AstraZeneca.

RegulatoryJuly 6, 2026

FDA Accepts Supplemental Application for SYMBICORT AEROSPHERE

The FDA has accepted a supplemental application for SYMBICORT AEROSPHERE, indicating progress in its regulatory review.

StrategyJuly 5, 2026

Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval

Teva Pharmaceuticals has received FDA approval for ANDA212212, a generic formulation of Budesonide and Formoterol Fumarate Dihydrate.

ClinicalJuly 4, 2026

AstraZeneca's PT010 Study Targets Severe Asthma in Adults and Adolescents

AstraZeneca is conducting a study to evaluate the efficacy and safety of PT010, a combination inhaler, in patients with inadequately controlled severe asthma.

ClinicalJune 29, 2026

Study on Near Fatal Asthma in Children to Inform Future Clinical Guidelines

A study led by the University of Edinburgh will investigate the frequency and risk factors of near fatal asthma in children aged 5-15 in the UK and ROI.

ClinicalJune 25, 2026

Study on TGF-beta's Role in Asthmatic Susceptibility to RSV Initiated

A clinical trial is investigating the role of TGF-beta in increasing susceptibility to RSV in individuals with asthma.

CompetitiveJune 25, 2026

Phase 2 Study of Rademikibart for Acute Asthma Exacerbation Initiated by Connect Biopharm

Connect Biopharm has initiated Phase 2 trial for Rademikibart as an add-on treatment for acute asthma exacerbations.

ClinicalJune 21, 2026

Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients

Amgen is conducting Phase 1 study to evaluate the safety and tolerability of AMG 691 in healthy participants and those with mild-to-moderate asthma.

StrategyJune 21, 2026

Budget Impact of Single-Inhaler Triple Therapy for Asthma in Saudi Arabia

The study evaluates the financial implications of introducing FF/UMEC/VI therapy for asthma in Saudi Arabia.

ClinicalJune 18, 2026

EVOLVE Study to Assess Real-World Effectiveness of Tezepelumab in Severe Asthma in Greece

The EVOLVE study will evaluate the real-world effectiveness of tezepelumab in uncontrolled severe asthma over two years in Greece.

RegulatoryJune 1, 2026

Breztri Gains US Approval as First Triple Therapy for Asthma

Breztri has been approved in the US as the first and only triple therapy for asthma in patients aged 12 and older, based on positive Phase III trial results.

Companies

Assets

Recent signals(20)